Given that COX-2-PGE2 signaling is governed by neutrophil A9 during tumor progression, the manipulation of A9 translocation from the cytoplasm to the nucleus may open new avenues for cancer treatments. The gene discussed is IGKV1D-22; the disease is cancer.